ImmuSAFE COVID Tests Product Range
ImmuSAFE™ can be utilised for vaccine clinical trials or sero-prevalence research studies.
Population antibody profiling for sero-prevalence research
The target epitope of antibodies produced following infection exhibit a significant level of diversity across a population. ImmuSAFE™ provides a more accurate determination of sero-prevalence by targeting over 10 different domains of SARS-CoV-2.
Determine the protective quality and quantity of antibodies produced
Some individuals produce antibodies that target locations which are neutralising (protective), whereas others produce non-neutralising antibodies. Identifying individuals who have high titres of potentially neutralising antibodies against SARS-CoV-2 that may protect against reinfection or provide indications as to whether booster vaccinations are required.
Enable quantitative assessment of patient response in vaccination trials
The determination of specific antigenic sites is crucial in vaccine development against COVID-19. The screening for immunoreactivity using the ImmuSAFE™ will facilitate the mass screening of COVID-19 samples for diagnosis and the identification of immunodominant epitopes, which is crucial for population-based (or even patient-centric) vaccine development.
ImmuSAFE™ is the world’s first multi-antigen biochip-based quantitative screening test for COVID-19
ImmuSAFE™ is a lab-based biochip test that utilises Sengenics’ patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites. More than ten domains of SARS-CoV-2 Nucleocapsid and Spike proteins including both full-length and numerous truncated versions are used in the tests.
Cross-reactivity between immunogenic regions of SARS-CoV-2 and other coronaviruses may lead to an overestimation of sero-prevalence in a given population. ImmuSAFE™ is designed to reduce cross-reactivity by targeting multiple SARS-CoV-2 specific domains, resulting in fewer false positives, and a more accurate determination of sero-prevalence.
The ImmuSAFE™ product range includes biochip-based tests that also incorporate additional viral antigens such as: SARS-CoV-2 Envelope, Nucleocapsid proteins from 13 other Coronaviruses including 5 human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes. Content can be customised based on individualised requirements for vaccine clinical trials or sero-prevalence research studies.
|39508H||ImmuSAFE™ COVID+ Protein Microarray
Contains multiple SARS-CoV-2 specific domains (Nucleocapsid and Spike proteins) including full-length and numerous truncated versions. Key applications are vaccine clinical trials and sero-prevalence research studies.
|39508V||ImmuSAFE™ Respiratory Virus Protein Microarray
Contains multiple SARS-CoV-2 proteins, Nucleocapsid proteins from 5 other human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes. Key application is sero-prevalence research studies.
|39508R||ImmuSAFE™ Discovery Virus Protein Microarray
Contains multiple SARS-CoV-2 proteins, Nucleocapsid proteins from 13 other Coronaviruses including 5 human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes. Key application is for research and development purposes.
All antigens are expressed in sf9 insect cells using the patented KREX functional proteomics technology. Viral antigens are full-length, correctly folded, functional, with both conformational and non-conformational antibody binding sites preserved. Each antigen is supplied as either lysate or purified protein.
© 2008 – 2020 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361